DERAMCICLANE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H31NO
Molecular Weight	301.4662
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCO[C@@]1(C[C@H]2CC[C@]1(C)C2(C)C)C3=CC=CC=C3

InChI

InChIKey=QOBGWWQAMAPULA-RLLQIKCJSA-N

InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H31NO
Molecular Weight	301.4662
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19963003 | https://www.ncbi.nlm.nih.gov/pubmed/15949921 | https://www.ncbi.nlm.nih.gov/pubmed/9551765

Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.

Approval Year

PubMed

Title	Date	PubMed
Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein.	2010-03	19720112
Deramciclane improves object recognition in rats: potential role of NMDA receptors.	2010-02	19963003
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.	2008-01	17971064
Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.	2005-12	15949921
Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human.	2005-11	16118331
Role of CYP2E1 in deramciclane metabolism.	2005-11	15932955
Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers.	2004-11	15451546
Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers.	2004-08	15366325
Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats.	2004-04	15099931
Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.	2004-02	14730412
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.	2003-12	14566442
The effect of oil as a dietary component on in vitro dissolution of an acid-labile drug.	2003-07	12894756
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration.	2003	14584962
Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds.	2002-03	11849919
In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers.	2002-03	11849912
Deramciclane (Egis).	2002-02	12020062
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze.	2001-01	11271409

Patents

Sample Use Guides

In Vivo Use Guide

60 mg/day

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:37 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:37 GMT 2025`
Record UNII	O5KFK61E74
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DERAMCICLANE [MI]

Preferred Name

English

DERAMCICLANE

Official Name

English

deramciclane [INN]

Common Name

English

Deramciclane [WHO-DD]

Common Name

English

Code System Code Type Description

INN

6838